PC-DAC: Exendin-4: Preliminary Phase I/II data

In a double-blind, placebo-controlled, dose-escalating Phase I/II trial in 42 patients, once-weekly single subcutaneous doses were well tolerated. Plasma concentrations were dose-dependent for the fir...